Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus

Back to Jobs

OTO -313 Phase 2 trial is fully enrolled ahead of schedule Top-line results for all timepoints expected in mid-2022 SAN DIEGO , Feb. 22, 2022 (GLOBE NEWSWIRE) — Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today

Apply Now